FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s – 16 or 15d – 16
of
the Securities Exchange Act of 1934
For the month of February 2005
Acambis plc
(Translation of registrant’s name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(Indicate by check mark whether
the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F).
Forms 20-F 
Form
40-F 
(Indicate by check mark whether
the registrant by furnishing the information contained in this Form is
also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No
(If “Yes” is marked,
indicate below the file number assigned to the registrant in connection with
Rule 12g3-2(b): 82- ).
Enclosure:
Schedule 10 Notification of Major Interests in
Shares.
Acambis to present at the Merrill Lynch Global Pharmaceutical, Biotechnology
& Medical Device Conference.
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
Legal & General Investment Management Limited
3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them
HSBC Global Custody Nominee (UK) Ltd – various accounts
5. Number of shares / amount of stock acquired
Not disclosed
6. Percentage of issued class
Not disclosed
7. Number of shares / amount of stock disposed
N/a
8. Percentage of issued class
N/a
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
Not disclosed
11. Date company informed
4 February 2005
12. Total holding following this notification
6,467,972 shares
13. Total percentage holding of issued class following this notification
6.03%
14. Any additional information
N/a
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0)
1223 275 300
16. Name and signature of authorised company official responsible for making this notification
Elizabeth Brown
Date of notification
7 February 2005
The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.
Acambis to present at
the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical
Device Conference
Cambridge, UK and Cambridge, MA – 8 February 2005 – Acambis
plc (“Acambis”) (LSE: ACM, NASDAQ: ACAM) announces that Gordon Cameron,
Chief Executive Officer, will be presenting at the Merrill Lynch Global Pharmaceutical,
Biotechnology & Medical Device Conference Wednesday, February 9, 2005
at 10:30 a.m. Eastern Time (3:30 p.m. GMT). The conference will be held at
the Grand Hyatt Hotel in New York.
A link to the live audio webcast of the presentation will be available on
the company’s web site at www.acambis.com.
Lyndsay Wright, Director of Communications - Tel: +44 (0) 1223 275 300
Tracy Paczkowski, Communications Associate - Tel: 617 761 4200
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Recognised internationally as a leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world. Acambis is establishing a travel vaccines franchise through its US-based subsidiary Berna Products Corporation, which markets Vivotif®, the world's only licensed oral typhoid vaccine, in North America. Acambis has a number of other potential travel vaccines in development and is also developing an investigational vaccine against the West Nile virus, which has spread to 46 US States in the last five years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary listing is on the London Stock Exchange (ACM) and its shares are listed in the form of American Depositary Receipts on NASDAQ (ACAM). More information is available at www.acambis.com.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant Peptide Therapeutics Group has duly
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| Date: 18 February 2005 | ACAMBIS PLC | |
| By: | /s/ Lyndsay Wright | |
| Name: Lyndsay Wright | ||
| Title: Director of Communications |